MedTrace Logo

Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

NCT04513184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-12-14

No results posted yet for this study

Summary

This Clinical Trial evaluates nasal administration of Dexamethasone as an adjuvant treatment strategy for non-critically ill hospitalized participants with SARS CoV-2 infection.

Conditions

  • Covid19

Interventions

DRUG

IV Dexamethasone

6 mg from Day 1 to 10 after randomization

DRUG

Nasal Dexamethasone

0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.

Sponsors & Collaborators

  • Hospital General de México Dr. Eduardo Liceaga

    collaborator OTHER_GOV

  • Instituto Nacional de Cardiologia Ignacio Chavez

    collaborator OTHER

  • El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

    collaborator OTHER

  • Edda Sciutto Conde

    lead OTHER

Principal Investigators

  • Edda Sciutto, PhD · Instituto de Investigaciones Biomédicas, UNAM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2021-11-12
Completion
2021-11-13

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513184 on ClinicalTrials.gov